OCT-1,ABCB1, andABCG2Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
Authors:
Open Access
- 1 January 2014
- journal article
- Published by Chonnam National University Medical School in Chonnam Medical Journal
- Vol. 50 (3) , 102-111
Abstract
Kim YK, et al. Chonnam Med J. 2014 Dec;50(3):102-111. http://dx.doi.org/10.4068/cmj.2014.50.3.102Keywords
This publication has 28 references indexed in Scilit:
- Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitorsHaematologica, 2012
- Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failedHaematologica, 2011
- Drug Transporters and Imatinib Treatment: Implications for Clinical PracticeClinical Cancer Research, 2011
- Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyLeukemia, 2010
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia, 2009
- Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistanceHematology-American Society Hematology Education Program, 2009
- Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood, 2006
- Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid LeukemiaClinical Cancer Research, 2006
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateLeukemia, 2006